SAN DIEGO and TORONTO, March 5,
2015 /CNW/ - Aptose Biosciences Inc. (NASDAQ: APTO,
TSX: APS), a clinical-stage company developing new therapeutics and
molecular diagnostics that target the underlying mechanisms of
cancer, today announced that William G.
Rice, Ph.D., Chairman, President and Chief Executive
Officer, will present at the upcoming 27th Annual ROTH Conference
on Tuesday, March 10th at
9:30 a.m. PT at the The Ritz Carlton,
Laguna Niguel, CA. Dr. Rice will
provide a corporate overview of the Company's recent activities and
strategic direction including plans to develop Aptose's lead
clinical agent, APTO-253 for acute myeloid leukemia (AML),
myelodysplastic syndromes (MDS) and other hematologic
malignancies.
A live audio webcast of the Aptose presentation will be
accessible by visiting:
http://wsw.com/webcast/roth29/apto
The audio webcast will be archived shortly after the live event
and will be available for 90 days through the Aptose website at
www.aptose.com.
About Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company
committed to discovering and developing personalized therapies
addressing unmet medical needs in oncology. Aptose is advancing new
therapeutics focused on novel cellular targets on the leading edge
of cancer research coupled with companion diagnostics to identify
the optimal patient population for our products. The company's
small molecule cancer therapeutics pipeline includes products
designed to provide additive or synergistic efficacy with existing
anti-cancer therapies and regimens without overlapping toxicities.
For further information, please visit
www.aptosebiosciences.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of Canadian and U.S. securities laws. Such statements
include, but are not limited to, statements relating to the
Company's plans, objectives, expectations and intentions and other
statements including words such as "continue", "expect", "intend",
"will", "should", "would", "may", and other similar expressions.
Such statements reflect our current views with respect to future
events and are subject to risks and uncertainties and are
necessarily based upon a number of estimates and assumptions that,
while considered reasonable by us are inherently subject to
significant business, economic, competitive, political and social
uncertainties and contingencies. Many factors could cause our
actual results, performance or achievements to be materially
different from any future results, performance or achievements
described in this press release. Such expressed or implied forward
looking statements could include, among others: our ability to
obtain the capital required for research and operations; the
inherent risks in early stage drug development including
demonstrating efficacy; development time/cost and the regulatory
approval process; the progress of our clinical trials; our ability
to find and enter into agreements with potential partners; our
ability to attract and retain key personnel; changing market
conditions; and other risks detailed from time-to-time in our
ongoing quarterly filings, annual information forms, annual reports
and annual filings with Canadian securities regulators and the
United States Securities and Exchange Commission.
Should one or more of these risks or uncertainties materialize,
or should the assumptions set out in the section entitled "Risk
Factors" in our filings with Canadian securities regulators and the
United States Securities and Exchange Commission underlying those
forward-looking statements prove incorrect, actual results may vary
materially from those described herein. These forward-looking
statements are made as of the date of this press release and we do
not intend, and do not assume any obligation, to update these
forward-looking statements, except as required by law. We cannot
assure you that such statements will prove to be accurate as actual
results and future events could differ materially from those
anticipated in such statements. Investors are cautioned that
forward-looking statements are not guarantees of future performance
and accordingly investors are cautioned not to put undue reliance
on forward-looking statements due to the inherent uncertainty
therein.
SOURCE Aptose Biosciences Inc.